MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies

Clinical Colorectal Cancer

Volumn 13, Issue 1, 2014, Pages

  Cappuzzo, Federico ^a   Sacconi, Andrea ^b   Landi, Lorenza ^a   Ludovini, Vienna ^c   Biagioni, Francesca ^b   D'Incecco, Armida ^a   Capodanno, Alessandra ^d   Salvini, Jessica ^a   Corgna, Enrichetta ^c   Cupini, Samanta ^a   Barbara, Cecilia ^a   Fontanini, Gabriella ^d   Crinò, Lucio ^c   Blandino, Giovanni ^b  

^a Livorno Hospital   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Cetuximab; Let 7c; miR 125b; miR 99a; Panitumumab

Indexed keywords

CETUXIMAB; IRINOTECAN; MICRORNA; MICRORNA 125B; MICRORNA 99A; MICRORNA LET 7C; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MICROARRAY ANALYSIS; MIDDLE AGED; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; WILD TYPE; YOUNG ADULT;

CETUXIMAB; LET-7C; MIR-125B; MIR-99A; PANITUMUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893210980     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.11.006     Document Type: Article

References (40)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J Clin 62 2012 10 29
2. A. de Gramont, A. Figer, and M. Seymour et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
3. J.Y. Douillard, D. Cunningham, and A.D. Roth et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
4. H. Hurwitz, L. Fehrenbacher, and W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
5. E. Van Cutsem, C.H. Köhne, and E. Hitre et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
6. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
7. C.M. Croce Causes and consequences of microRNA dysregulation in cancer Nat Rev Genet 10 2009 704 714
8. M. Ragusa, A. Majorana, and L. Statello et al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment Mol Cancer Ther 9 2010 3396 3409
9. A. Ruzzo, F. Graziano, and B. Vincenzi et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease Oncologist 17 2012 823 829
10. B.C. Christensen, B.J. Moyer, and M. Avissar et al. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers Carcinogenesis 30 2009 1003 1007
11. W. Zhang, T. Winder, and Y. Ning et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy Ann Oncol 22 2011 104 109
12. G.J. Weiss, L.T. Bemis, and E. Nakajima et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines Ann Oncol 19 2008 1053 1059
13. W.C. Cho, A.S. Chow, and J.S. Au Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation Eur J Cancer 45 2009 2197 2206
14. M. Garofalo, G. Romano, and G. Di Leva et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers Nat Med 18 2011 74 82
15. F. Cappuzzo, G. Finocchiaro, and E. Rossi et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 2008 717 723
16. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1985 457 481
18. John D. Storey A direct approach to false discovery rates Journal of the Royal Statistical Society 64 2002 479 498
19. S. Misale, R. Yaeger, and S. Hobor et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
20. W. De Roock, V. De Vriendt, and N. Normanno et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer Lancet Oncol 12 2011 594 603
21. B. Dufourny, J. Alblas, and H.A. van Teeffelen et al. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase J Biol Chem 272 1997 31163 31171
22. H.M. Khandwala, I.E. McCutcheon, and A. Flyvbjerg et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth Endocr Rev 21 2000 215 244
23. R. Baserga, M. Resnicoff, and M. Dews The IGF-I receptor and cancer Endocrine 7 1997 99 102
24. V.A. Blakesley, B.S. Stannard, and T. Kalebic et al. Role of the IGF-I receptor in mutagenesis and tumor promotion J Endocrinol 152 1997 339 344
25. K. Yonesaka, K. Zejnullahu, and I. Okamoto et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Sci Transl Med 3 2011 99ra86
26. V. Martin, L. Landi, and F. Molinari et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients Br J Cancer 108 2013 668 675
27. A. Chakravarti, J.S. Loeffler, and N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res 62 2002 200 207
28. M. Guix, A.C. Faber, and S.E. Wang et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins J Clin Invest 118 2008 2609 2619
29. A. Hakam, T.J. Yeatman, and L. Lu et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer Hum Pathol 30 1999 1128 1133
30. M.M. Weber, C. Fottner, and S.B. Liu et al. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas Cancer 95 2002 2086 2095
31. T. Xie, G. D'Ario, and J.R. Lamb et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations PLoS One 7 2012 e42001
32. M.S. Kumar, J. Lu, and K.L. Mercer et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis Nat Genet 39 2007 673 677
33. S.M. Johnson, H. Grosshans, and J. Shingara et al. RAS is regulated by the let-7 microRNA family Cell 120 2005 635 647
34. C. Shang, Y.M. Lu, and L.R. Meng MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2 Med Sci Monit 18 2012 BR149 BR155
35. G.K. Scott, A. Goga, and D. Bhaumik et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b J Biol Chem 282 2007 1479 1486
36. H. Yamada, K. Yanagisawa, and S. Tokumaru et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer Genes Chromosomes Cancer 47 2008 810 818
37. D. Sun, Y.S. Lee, and A. Malhotra et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation Cancer Res 71 2011 1313 1324
38. J.W. Catto, S. Miah, and H.C. Owen et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer Cancer Res 69 2009 8472 8481
39. J. Dong, A. Sereno, and W.B. Snyder et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity J Biol Chem 286 2011 4703 4717
40. T.C. Chang, D. Yu, and Y.S. Lee et al. Widespread microRNA repression by Myc contributes to tumorigenesis Nat Genet 40 2008 43 50